Adam Luginbuhl
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University · Thomas Jefferson University
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Adam Luginbuhl as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 16:42 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT03854032 · Nivolumab and BMS986205 in Treating Patients With Stage II-IV Squamous Cell Cancer of the Head and NeckThomas Jefferson University · terminated · Lip, Oral Cavity Squamous Cell Carcinoma, Pharynx · principal investigator
- Early Ph1NCT03238365 · Window of Opportunity Trial of Nivolumab and Tadalafil in Patients With Squamous Cell Carcinoma of the Head and NeckSidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University · completed · Lip, Oral Cavity and Pharynx, Larynx · principal investigator
- Early Ph1NCT03109873 · Metformin Hydrochloride in Affecting Cytokines and Exosomes in Patients With Head and Neck CancerSidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University · completed · Larynx, Lip, Oral Cavity · principal investigator
- Early Ph1NCT02467738 · Surgical Resection and Intraoperative Cesium-131 Brachytherapy for Head and Neck CancerSidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University · completed · Recurrent Head and Neck Carcinoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 16:42 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 16:42 UTC. The ranking covers the 200 most relevant of 12 PubMed records, and a shared surname and initials can bring in a namesake. All 12 on PubMed
- Tadalafil Enhances Immune Signatures in Response to Neoadjuvant Nivolumab in Resectable Head and Neck Squamous Cell Carcinoma.Clin Cancer Res · 202260 citationsRCR 4.0
- Metformin effects on head and neck squamous carcinoma microenvironment: Window of opportunity trial.Laryngoscope · 201757 citationsRCR 2.0
- Metformin Effects on FOXP3+ and CD8+ T Cell Infiltrates of Head and Neck Squamous Cell Carcinoma.Laryngoscope · 202032 citationsRCR 1.5
- Nivolumab and ipilimumab in combination with radiotherapy in patients with high-risk locally advanced squamous cell carcinoma of the head and neck.J Immunother Cancer · 202318 citationsRCR 1.4
- Subcutaneous vs intramuscular botulinum toxin: split-face randomized study.JAMA Facial Plast Surg · 201416 citationsRCR 1.2
- Response-Adaptive Surgical Timing in Neoadjuvant Immunotherapy Demonstrates Enhanced Pathologic Treatment Response in Head and Neck Squamous Cell Carcinoma.Clin Cancer Res · 202512 citationsRCR 2.7
- Prospective, randomized, controlled trial using best-selling smoking-cessation book.Ear Nose Throat J · 20177 citationsRCR 0.4
- In-Field Toxicity Analysis of a Phase 1 Clinical Trial of Nivolumab and Ipilimumab With Definitive Radiation Therapy in Locally Advanced Squamous Cell Carcinoma of the Head and Neck.Int J Radiat Oncol Biol Phys · 20236 citationsRCR 0.5
- A Randomized Pilot Trial of Virtual Reality Surgical Planning for Head and Neck Oncologic Resection.Laryngoscope · 20256 citationsRCR 5.1
- Extracellular Matrix-MYCAF Signatures Correlate with Resistance to Neoadjuvant aPD-L1 Immune Checkpoint Inhibition with Durvalumab + Metformin in HPV+ HNSCC.Clin Cancer Res · 20256 citationsRCR 1.2